dc.contributor.author | Ohno, Shigeaki | |
dc.contributor.author | Gül, Ahmet | |
dc.date.accessioned | 2021-03-05T07:39:12Z | |
dc.date.available | 2021-03-05T07:39:12Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Gül A., Ohno S., "HLA-B*51 and Behcet Disease", OCULAR IMMUNOLOGY AND INFLAMMATION, cilt.20, ss.37-43, 2012 | |
dc.identifier.issn | 0927-3948 | |
dc.identifier.other | av_94e50aab-b4cc-476b-aa91-543fbba04020 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/100275 | |
dc.identifier.uri | https://doi.org/10.3109/09273948.2011.634978 | |
dc.description.abstract | Behcet disease (BD) is a multisystem inflammatory disorder of unknown etiology. BD has a multifactorial pathogenesis, and genetics plays a critical role in the development of the disease. Association of HLA-B5/B*51 has been recognized as the strongest genetic susceptibility factor for BD discovered so far. Pathogenic role of HLA-B*51 in BD has yet to be clarified, and available data suggest that there is possibly no single mechanism associated with HLA-B*51. HLA-B*51 may accomplish its effects as a combination of different HLA class I-associated functions and/or structural properties of HLA-B*51 heavy chain. There is no evidence supporting the use of HLA-B*51 as a diagnostic or prognostic marker for BD, and more clinical data must be collected in addition to basic immunological studies to exploit the potential of HLA-B*51 as a biomarker for BD management. | |
dc.language.iso | eng | |
dc.subject | Göz Hastalıkları ve Cerrahisi | |
dc.subject | Cerrahi Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | OFTALMOLOJİ | |
dc.title | HLA-B*51 and Behcet Disease | |
dc.type | Makale | |
dc.relation.journal | OCULAR IMMUNOLOGY AND INFLAMMATION | |
dc.contributor.department | Hokkaido Üniversitesi , , | |
dc.identifier.volume | 20 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 37 | |
dc.identifier.endpage | 43 | |
dc.contributor.firstauthorID | 50865 | |